Novo Norsesk flags Wegovy birth control pills, losing weight, walking with injection

Novo Nordsk He said on Wednesday that the results of the late trial of the love of obesity that were on a day daily showed a “significant decrease in weight” and tolerance in line with the tied Wegov injections, as drug makers compete to obtain oral treatment to the market.

The results of the trial of stage 3 Oasis 4 showed that the pill in the orally, led to a decrease in the average weight by 16.6 % after 64 weeks in patients with obesity or weight gain, and at least one subscriber linked to weight.

The shares jumped by 5.4 % by 10:23 am London time (5:23 am EST).

Martin Holst Lang, chief science official at Novo Nordsek, Martin Holst Lang, told CNBC that oral treatment has provided an important alternative to patients from his injection once a week.

“Our mission was to show that, with the tablet, we can get the same event and the same safety and endurance as we can with the injection. We did now.”

He added: “This means that we can provide patients with the choice between the tablet and injection, and this will happen as a difference for some patients.”

Novo Nordisk transmits orally on the same Semaglutide GLP-1 which supports the company’s obesity and diabetes treatments for the company, Wigofi and Ozmbach. It has been shown that Wigoufi reduces weight by 15 % on average in patients with weight gain or obesity, and a joint disorder, at least in the previous Novo study.

The pill is currently being reviewed with the US Food and Drug Administration, as it was submitted under a new drug request in February. A worthy decision in the fourth quarter of this year.

If approved, the company said that the pill will be fully made in the United States, as was international pharmaceutical companies The intensification of their investments in the United States Amid pressure from the Trump administration to enhance local production.

Analysts He said Reuters on Tuesday this competitor Eli LilyThe competing obesity can be tracked, Orforglipron, to be approved within a month to two months under the “Commissioner of the Commissioner of the Commissioner of the Commissioner for the Commissioner of the Commissioner for the Food and Drugs-a new initiative to enhance the goals of drug management in the Trump administration.

Lango said that Novo welcomes “good competition”, but added that it focuses on drug results, including long -term adoption rates.

“In this case, we look at the data,” Lang said. “For a lapse, a gym can be owned by a 17 % body weight loss device and with a good profile for safety and endurance.”

“What we have seen from our competitor is a little more than 12 % weight loss. Once again, we cannot make comparisons directly, but at least we can see a stop rate, indicating that heavenly stability may also have (more) an effective file for safety and endurance.”

In stage 3 ACAIN-1 trial was issued on TuesdayElie Lily said that Ovor Glipron has resulted in a medium weight loss by 12.4 % at the highest dose after 72 weeks in obese adults, or weight gain with at least one common disorder.

However, the American drug maker said on Wednesday that the birth control pills surpassed Novo in the first A face -to -face study Comparing the effectiveness of medications in reducing blood sugar levels in patients with type 2 diabetes.

Both companies have tried the so -called drugs from the next generation, with Novo on Tuesday The associated promise In analog amylin analog-a form of weight loss treatment.

It comes at a time when the Danish company announced last week plans Reduce about 9,000 roles As part of the disposal of the new CEO Mike Dutedar, who pledged to reset the company after a period of weakest growth.

“What we are doing now is to focus on our essence, which is diabetes and obesity. This will include continuous investment in both diabetes and obesity, as well, as we discussed, accompanying related diseases,” Lang said on Wednesday.